Literature DB >> 10997744

Clinical criteria and biochemical markers for the detection of systolic dysfunction.

K Yamamoto1, J C Burnett, E A Bermudez, M Jougasaki, K R Bailey, M M Redfield.   

Abstract

BACKGROUND: This study was designed to assess the use of clinical criteria and biochemical testing to detect systolic dysfunction. Our goal is to develop strategies that may enhance the detection and treatment of patients with early ventricular dysfunction while reducing the use of echocardiography. METHODS AND
RESULTS: We compared the predictive characteristics of the plasma brain natriuretic peptide (BNP) concentration with that of a 5-point clinical score derived from elements of the history, electrocardiogram, and chest radiograph in outpatients (n = 466) referred for echocardiography because of symptoms of heart failure or risk factors for systolic dysfunction. Systolic dysfunction was defined as an ejection fraction (EF) less than 45% and was present in 10.9% of patients. By receiver operating characteristic analysis, BNP was sensitive and specific for the detection of systolic dysfunction, with an area under the receiver operating characteristic curve for the detection of EF less than 45% of 0.79. The BNP assay was abnormal in 41% of patients and identified a group with a high prevalence of systolic dysfunction (21% with an EF less than 45%), whereas a normal BNP value identified a group with a low prevalence of systolic dysfunction (4% with an EF less than 45%). The clinical score was positive in 43% of the population and identified a group with a high prevalence of systolic dysfunction (24% with an EF less than 45%). A normal score identified a group with a low prevalence of systolic dysfunction (1% with an EF less than 45%).
CONCLUSION: This study supports previous studies, which showed that BNP assay predicts systolic dysfunction with acceptable sensitivity and specificity, and it underscores the effectiveness of additional readily available clinical criteria. Both of these strategies should be considered in screening for left ventricular dysfunction in populations at risk while limiting expensive cardiac imaging modalities.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997744     DOI: 10.1054/jcaf.2000.9676

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  16 in total

Review 1.  Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis.

Authors:  Clare Davenport; Elaine Yee Lan Cheng; Yip Tung Tony Kwok; Annie Hiu On Lai; Taka Wakabayashi; Chris Hyde; Martin Connock
Journal:  Br J Gen Pract       Date:  2006-01       Impact factor: 5.386

2.  Effectiveness of transcendental meditation on functional capacity and quality of life of African Americans with congestive heart failure: a randomized control study.

Authors:  Ravishankar Jayadevappa; Jerry C Johnson; Bernard S Bloom; Sanford Nidich; Shashank Desai; Sumedha Chhatre; Donna B Raziano; Robert Schneider
Journal:  Ethn Dis       Date:  2007       Impact factor: 1.847

Review 3.  Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.

Authors:  Min-Seok Kim; Ju-Hee Lee; Eung Ju Kim; Dae-Gyun Park; Sung-Ji Park; Jin Joo Park; Mi-Seung Shin; Byung Su Yoo; Jong-Chan Youn; Sang Eun Lee; Sang Hyun Ihm; Se Yong Jang; Sang-Ho Jo; Jae Yeong Cho; Hyun-Jai Cho; Seonghoon Choi; Jin-Oh Choi; Seong Woo Han; Kyung Kuk Hwang; Eun Seok Jeon; Myeong-Chan Cho; Shung Chull Chae; Dong-Ju Choi
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

4.  B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study.

Authors:  Kirsten Bibbins-Domingo; Maria Ansari; Nelson B Schiller; Barry Massie; Mary A Whooley
Journal:  Circulation       Date:  2003-12-08       Impact factor: 29.690

5.  Assessment of cardiac involvement of hepatitis C virus; tissue Doppler imaging and NTproBNP study.

Authors:  Ahmed Saleh; Akira Matsumori; Hany Negm; Hany Fouad; Ahmed Onsy; Mohammed Shalaby; Enas Hamdy
Journal:  J Saudi Heart Assoc       Date:  2011-05-23

6.  Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study.

Authors:  Kirsten Bibbins-Domingo; Maria Ansari; Nelson B Schiller; Barry Massie; Mary A Whooley
Journal:  Am J Med       Date:  2004-04-15       Impact factor: 4.965

7.  Serum markers of systemic right ventricular function and exercise performance.

Authors:  Ruchira Garg; Subha V Raman; Timothy M Hoffman; John Hayes; Curt J Daniels
Journal:  Pediatr Cardiol       Date:  2008-01-10       Impact factor: 1.655

8.  The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population.

Authors:  I Raymond; B A Groenning; P R Hildebrandt; J C Nilsson; M Baumann; J Trawinski; F Pedersen
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

9.  Preprocedural N-terminal pro-brain natriuretic peptide (NT-proBNP) is similar to the Mehran contrast-induced nephropathy (CIN) score in predicting CIN following elective coronary angiography.

Authors:  Yong Liu; Yi-ting He; Ning Tan; Ji-yan Chen; Yuan-hui Liu; Da-hao Yang; Shui-jin Huang; Piao Ye; Hua-long Li; Peng Ran; Chong-yang Duan; Shi-qun Chen; Ying-ling Zhou; Ping-yan Chen
Journal:  J Am Heart Assoc       Date:  2015-04-17       Impact factor: 5.501

Review 10.  The accuracy of symptoms, signs and diagnostic tests in the diagnosis of left ventricular dysfunction in primary care: a diagnostic accuracy systematic review.

Authors:  V Madhok; G Falk; A Rogers; A D Struthers; F M Sullivan; T Fahey
Journal:  BMC Fam Pract       Date:  2008-10-08       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.